Enjoy complimentary customisation on priority with our Enterprise License!
The hyperparathyroidism market size is forecast to increase by USD 486.7 million at a CAGR of 7.1% between 2023 and 2028. The market is experiencing significant growth due to the increasing awareness of thyroid disorders and the subsequent rise in diagnoses. Benign tumors in the parathyroid glands, leading to hyperparathyroidism, are a common cause of bone pain and calcium imbalances. The diagnosis of hyperparathyroidism involves a series of tests, including blood tests to measure calcium and PTH levels, and imaging tests such as a parathyroid scan to locate the source of the overactive gland. To diagnose this condition, healthcare professionals utilize calcium blood tests and PTH blood tests, along with assessments of bone mineral density and vitamin D deficiency. companies in this market are implementing strategic acquisitions and collaborations to expand their reach and offerings. However, stringent regulations impose challenges on market growth, requiring companies to adhere to rigorous standards and guidelines.
Hyperparathyroidism is a medical condition characterized by excessive production of parathyroid hormone (PTH) by the parathyroid glands. This condition can lead to elevated levels of calcium in the blood, a condition known as hypercalcemia, and imbalanced levels of calcium and phosphate in the body. Primary hyperparathyroidism (PHPT) is the most common form of the disease, where single or multiple parathyroid glands become overactive. Secondary and tertiary hyperparathyroidism are less common forms of the condition, caused by kidney disease and long-term use of certain medications, respectively. Symptoms of hyperparathyroidism can include joint pain, muscle weakness, fatigue, depression, kidney disease, osteoporosis, and kidney stones.
Moreover, the condition can also lead to calcium deposition in various organs, causing damage and complications. Management of hyperparathyroidism focuses on controlling the symptoms and preventing complications. Treatment options include surgery, such as parathyroidectomy, to remove the overactive gland, and medications like calcimimetics to help regulate calcium levels in the body. Prevention of hyperparathyroidism involves maintaining a healthy lifestyle, including a balanced diet and regular exercise.
In conclusion, early detection and prompt treatment are essential to prevent complications and improve the outlook for individuals with the condition. The prognosis for hyperparathyroidism depends on the severity of the condition and the timeliness of the diagnosis and treatment. With proper management, individuals with hyperparathyroidism can lead normal, active lives. Hyperparathyroidism is a complex medical condition that affects various systems in the body. Understanding its symptoms, diagnosis, management, and treatment options is crucial for individuals diagnosed with the condition and their healthcare providers. Regular follow-up care and ongoing communication between patients and healthcare professionals are essential to ensure optimal health outcomes.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.
The secondary hyperparathyroidism segment is estimated to witness significant growth during the forecast period. Secondary hyperparathyroidism is a notable condition within the market, linked to the advancement of chronic kidney disease. As kidney function deteriorates, the parathyroid glands become overactive, resulting in excessive parathyroid hormone (PTH) production. This hormonal imbalance triggers various physiological responses that pose health risks. One major consequence is the release of phosphorus and calcium from bones into the bloodstream, leading to decreased bone density and an increased susceptibility to fractures. Furthermore, the elevated levels of these minerals in the blood can cause ectopic calcification, where they deposit in non-skeletal tissues. This condition can result in complications such as joint pain and muscle weakness.
Moreover, the outlook for secondary hyperparathyroidism is challenging, with a focus on effective management and prevention. Treatment options include medications to control PTH levels, calcium and phosphate binders, and vitamin D supplements. The prognosis for individuals with secondary hyperparathyroidism depends on the underlying cause and the severity of kidney disease. Regular monitoring and timely intervention are crucial to mitigate the health risks associated with this condition.
Get a glance at the market share of various segments Request Free Sample
The secondary hyperparathyroidism segment was valued at USD 431.00 million in 2018 and showed a gradual increase during the forecast period.
North America is estimated to contribute 35% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
For more insights on the market share of various regions Request Free Sample
The market in North America, specifically in the United States, is marked by substantial healthcare expenditures and a considerable prevalence of this endocrine disorder. In 2023, US healthcare spending reached an impressive USD 4.8 trillion, registering a growth rate of 7.5% over the previous year. This figure surpassed the projected annual GDP growth rate of 6.1%, indicating a considerable investment in healthcare services and infrastructure. Hyperparathyroidism is a common condition in the US, particularly among women and older adults. Given the higher incidence of this disease in these demographic groups, it is essential to develop targeted healthcare strategies to cater to their unique needs.
Also, phosphate binders and Vitamin D are commonly used treatments for managing hyperparathyroidism. Self-care tips, such as maintaining proper hydration and following a balanced diet, are crucial for managing the disease effectively. Risk factors for complications include dehydration, malnutrition, and kidney stones. Ensuring access to appropriate healthcare services and increasing awareness about the disease can help mitigate these risks and improve patient outcomes.
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The rise in thyroid treatment awareness programs is the key driver of the market. The market is witnessing notable expansion due to heightened awareness and education surrounding thyroid gland health. Notable initiatives, such as World Thyroid Day observed on May 25th each year, contribute significantly to this growth. This day is marked by informative events, including presentations and seminars, organized by healthcare providers, medical institutions, and advocacy groups.
Moreover, these activities aim to enlighten the public about various thyroid conditions, their underlying causes, and the available treatment alternatives. Furthermore, January is acknowledged worldwide as Thyroid Awareness Month, intensifying efforts to spread awareness on thyroid diseases. The significance of the thyroid gland in maintaining calcium absorption and regulating phosphorus levels in the body underscores the importance of proper diagnosis and treatment.
The increasing inorganic growth strategies among companies is the upcoming trend in the market. The market in the United States is witnessing a significant trend among companies toward strategic expansion. This growth strategy involves partnerships, licensing deals, and acquisitions to broaden market presence and enhance product offerings. An illustration of this trend is the agreement between EA Pharma Co., Ltd. And Pathalys Pharma, Inc., announced in March 2022. Under this arrangement, Pathalys Pharma obtained a worldwide exclusive license to develop and commercialize a treatment for secondary hyperparathyroidism in hemodialysis patients, excluding Japan, South Korea, China, Taiwan, and ASEAN countries.
Moreover, this strategic move showcases a focused approach to market segmentation and regional targeting. The market is undergoing a notable shift as companies adopt strategic expansion tactics. These tactics encompass collaborations, licensing agreements, and acquisitions, which are instrumental in expanding market coverage and improving product lines. An instance of this trend is the accord between EA Pharma Co., Ltd. And Pathalys Pharma, Inc., revealed in March 2022. According to the agreement, Pathalys Pharma secured a worldwide exclusive license to manufacture and distribute a remedy for secondary hyperparathyroidism in hemodialysis patients, with the exception of Japan, South Korea, China, Taiwan, and ASEAN countries. This strategic maneuver underscores a targeted approach to market segmentation and regional emphasis.
The stringent regulations is a key challenge affecting the market growth. The market is subject to rigorous regulatory oversight, particularly from the Food and Drug Administration (FDA. This regulatory landscape ensures that new treatments for conditions such as hyperparathyroidism meet the highest standards of quality and efficacy. For instance, the FDA's approval process for cinacalcet, a drug used to treat hyperparathyroidism, involves extensive evaluation. In April 2020, the FDA granted approval to Accordpharma's cinacalcet, finding it to be equivalent in quality and bioequivalent to the established drug Mimpara. This decision highlights the FDA's commitment to ensuring patient safety and therapeutic effectiveness by rigorously assessing new treatments. Hyperparathyroidism is a condition characterized by the growth of benign tumors in the parathyroid glands, leading to excessive production of parathyroid hormone (PTH).
Similarly, symptoms include bone pain, calcium and phosphorus imbalances, and bone mineral density loss. In some cases, vitamin D deficiency may also contribute to the development of hyperparathyroidism. Diagnosis involves calcium and PTH blood tests, and bone mineral density assessments. Treatment options include surgery, medication, and vitamin D supplementation. Cinacalcet, a calcimimetic agent, is a commonly used medication for managing hyperparathyroidism. Its approval by regulatory bodies underscores the importance of thorough evaluation and regulatory compliance in the healthcare industry.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
AbbVie Inc. - The company offers medications for hyperparathyroidism such as ZEMPLAR capsules.
The market research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Hyperparathyroidism is a condition characterized by the overproduction of parathyroid hormone (PTH) by one or more of the four parathyroid glands. This hormone plays a crucial role in regulating calcium and phosphate levels in the body. However, excessive production of PTH can lead to hypercalcemia, or high levels of calcium in the blood. Symptoms of hyperparathyroidism include joint pain, muscle weakness, fatigue, depression, kidney disease, and bone pain. The condition can be caused by various factors, including parathyroid adenoma, a benign tumor, hyperplasia, or cancer. Diagnosis involves a series of tests, including calcium and phosphate blood tests, parathyroid scan, and bone mineral density assessment.
Moreover, the management of hyperparathyroidism includes self-care tips, such as maintaining hydration and following a healthy diet. Medications like calcimimetics, bisphosphonates, phosphate binders, and vitamin D may be prescribed to manage symptoms and prevent complications. In severe cases, surgery, specifically parathyroidectomy, may be necessary. Risk factors for hyperparathyroidism include genetic syndromes, radiation exposure, and physical exam findings. Complications of the condition include osteoporosis, kidney stones, and hypoparathyroidism. Regular check-ups with a healthcare provider are essential for managing the condition and preventing complications.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
206 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 7.1% |
|
Market growth 2024-2028 |
USD 486.7 million |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
6.7 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 35% |
|
Key countries |
US, China, Germany, UK, France, India, Japan, Brazil, Italy, and South Korea |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
AbbVie Inc., Accord Healthcare Ltd., AdvaCare Pharma, Alkem Laboratories Ltd., Amgen Inc., Ascendis Pharma AS, Aurobindo Pharma Ltd., Biocon Ltd., Cipla Inc., Dr Reddys Laboratories Ltd., EA Pharma Co. Ltd., F. Hoffmann La Roche Ltd., Fresenius SE and Co. KGaA, Lupin Ltd., Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., and Zydus Lifesciences Ltd. |
|
Market dynamics |
Parent market analysis, market growth inducers and obstacles, market forecast, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, market condition analysis for the forecast period |
|
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Technavio Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Qualitative Analysis
7 Five Forces Analysis
8 Market Segmentation by Disease Type
9 Market Segmentation by Distribution Channel
10 Customer Landscape
11 Geographic Landscape
12 Drivers, Challenges, and Opportunity/Restraints
13 Competitive Landscape
14 Competitive Analysis
15 Appendix
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
Secondary sources
DATA ANALYSIS
Data Synthesis
Data Validation
REPORT WRITING
Qualitative
Quantitative
Get the report (PDF) sent to your email within minutes.
Complimentary full Excel data with your report purchase.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
